손발톱진균증 치료 시장 규모, 점유율, 성장 분석 : 종류별, 유통 경로별, 치료법별, 지역별 - 업계 예측(2026-2033년)

Onychomycosis Treatment Market size was valued at USD 5.33 Billion in 2024 and is poised to grow from USD 5.79 Billion in 2025 to USD 11.2 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The onychomycosis treatment market focuses on addressing nail fungal infections through various modalities, including topical solutions, laser therapies, and oral antifungal medications. A rise in onychomycosis cases, enhanced treatment options, and increased awareness are key drivers of market expansion. Additionally, rising healthcare expenditures enable broader access to advanced therapies. However, high treatment costs and potential side effects present challenges to market growth, as many advanced options, such as laser therapies and oral medications, can be prohibitively expensive and may pose risks like liver damage or gastrointestinal issues, causing patient reluctance. Nonetheless, the market is poised for growth through innovations in drug development, including advancements in drug delivery systems utilizing nanotechnology, sustained-release formulations, and effective topical treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Onychomycosis Treatment Market Segments Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Onychomycosis Treatment Market

The expanding incidence of fungal nail infections driven by an aging population, rising diabetes prevalence, and an increase in immune-compromising conditions is propelling the onychomycosis treatment market. Additionally, heightened awareness about the condition among patients, coupled with improved diagnostic capabilities and advanced treatment options recognized by healthcare professionals, is leading to a surge in diagnoses. This growing recognition and understanding of onychomycosis are significantly contributing to the demand for effective treatments, as both patients and providers seek better solutions for managing this prevalent condition. As a result, the market is witnessing substantial growth driven by these interrelated factors.

Restraints in the Onychomycosis Treatment Market

Currently, various treatments available for Onychomycosis may not provide adequate effectiveness for every patient, leading to a higher likelihood of recurrence of the condition. The efficacy of these treatments can vary based on the specific type and severity of the fungal infection, highlighting the importance of ongoing research and development in this area. As different patients respond uniquely to treatments, there is an increasing demand for innovative solutions that can cater to the diverse needs of those affected by Onychomycosis. Addressing these limitations is crucial for advancing treatment options and improving patient outcomes.

Market Trends of the Onychomycosis Treatment Market

The Onychomycosis Treatment market is witnessing a notable trend toward advanced laser therapies, particularly the adoption of Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers are gaining prominence due to their ability to deeply penetrate nail tissues, effectively targeting stubborn fungal infections. This technology is complementing traditional treatments and is preferred for its precision and efficacy. Meanwhile, Blue Light lasers are emerging as a viable option for milder infections or as an adjunct to other therapeutic modalities, harnessing heat energy to combat fungi. This shift towards innovative laser treatments reflects a growing demand for less invasive, effective solutions in the nail fungus treatment segment.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• PESTEL Analysis
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Onychomycosis Treatment Market by Treatment Type

• Market Overview
• Drugs
  • Oral
  • RX
  • OTC
  • Tropical
  • RX
  • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

• Market Overview
• 0 to 18 Years
• 19 to 39 Years
• 40 to 64 Years
• 65 Years & Above

Onychomycosis Treatment Market by Gender

• Market Overview
• Male
• Female

Onychomycosis Treatment Market by Distribution Channel

• Market Overview
• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medimetriks Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moberg Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sientra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments